表紙
市場調查報告書

關注市場分析:被套細胞淋巴瘤 (MCL)

Market Spotlight: Mantle Cell Lymphoma

出版商 Datamonitor Healthcare 商品編碼 912156
出版日期 內容資訊 英文 47 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關注市場分析:被套細胞淋巴瘤 (MCL) Market Spotlight: Mantle Cell Lymphoma
出版日期: 2019年11月29日內容資訊: 英文 47 Pages
簡介

本報告提供全球被套細胞淋巴瘤 (MCL) 市場相關調查,疾病的背景、概要,治療方法,開發平台治療藥概要,臨床試驗狀況等資料彙整。

概要

要點

疾病的背景

  • 疾病定義
  • 患者區分
  • 症狀
  • 風險因素
  • 診斷

治療方法

  • 標靶治療
  • 化療
  • 類固醇
  • 放射線治療
  • 蛋白梅體抑制劑
  • 幹細胞移植

流行病學

  • 盛行率

已上市藥物

開發平台藥物

近幾年趨勢、分析師的意見

  • Copiktra
  • Revlimid
  • Zevalin
  • Zanubrutinib
  • Venclexta

今後趨勢

主要的法規趨勢

  • BeiGene 活用中國的資料 獲得對Zanubrutinib的劃時代的狀態

成功的可能性

授權、資產獲得契約

  • 醫療產業形成的契約

本源專利

商機

臨床試驗環境

  • 贊助商:各進展狀況
  • 贊助商:各階段

文獻

  • 處方資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0203935

This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 14,030 incident cases of mantle cell lymphoma (MCL) worldwide, and forecasts that number to increase to 18,010 incident cases by

2026. It is estimated that the majority of diagnosed cases were male in

2017. The incidence of MCL is highest among older individuals aged 60+ years. Approved drugs in the MCL space focus on a wide variety of targets. The majority of these drugs are administered via the oral route, with the remainder being available in intravenous and subcutaneous formulations.

The majority of industry-sponsored drugs in active clinical development for MCL are in Phase II. Therapies in active clinical development for MCL focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.

High-impact upcoming events for drugs in the MCL space comprise topline Phase II trial results for KTE-X19 and parsaclisib, topline Phase II/III trial results for TG-1303 and umbralisib, and topline Phase III trial results for Imbruvica and Venclexta.

The overall likelihood of approval of a Phase I hematologic asset is 9.6%, and the average probability a drug advances from Phase III is 58.5%. Drugs, on average, take 8.9 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been five licensing and asset acquisition deals involving MCL drugs during 2014-19. The largest deal was the $391.5m strategic collaboration and licensing agreement between Innovent and Incyte in 2018 to develop and commercialize Incyte's pemigatinib, itacitinib, and parsaclisib for hematology and oncology indications in China.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for MCL have been in the early and mid-phases of development, with 90% of trials in Phase I-II, and only 10% in Phase III-IV.

The US has a substantial lead in the number of MCL clinical trials globally. France and Germany lead the major EU markets, while South Korea has the top spot in Asia.

Johnson & Johnson has the highest number of completed clinical trials for MCL, with 13 trials. Johnson & Johnson leads industry sponsors with the highest overall number of clinical trials for MCL, followed by Celgene and Takeda.

TABLE OF CONTENTS

CONTENTS

6 OVERVIEW

7 KEY TAKEAWAYS

8 DISEASE BACKGROUND

8 Disease definition

8 Patient segmentation

8 Symptoms

8 Risk factors

9 Diagnosis

10 TREATMENT

10 Targeted therapies

10 Chemotherapies

10 Steroids

11 Immunomodulators

11 Radiation therapy

11 Proteasome inhibitors

11 Stem cell transplantation

12 EPIDEMIOLOGY

17 MARKETED DRUGS

20 PIPELINE DRUGS

26 RECENT EVENTS AND ANALYST OPINION

26 Copiktra for MCL (July 25, 2019)

26 Copiktra for MCL (March 6, 2019)

27 Revlimid for MCL (February 27, 2019)

28 Zevalin for MCL (January 17, 2019)

29 Brukinsa for MCL (December 1, 2018)

31 Brukinsa for MCL (December 1, 2018)

34 KEY UPCOMING EVENTS

35 KEY REGULATORY EVENTS

35 Brukinsa Sprints To Accelerated Approval For MCL

35 Accord Gets EMA Support For Arsenic Trioxide

35 BeiGene Wins Breakthrough Status For Zanubrutinib With Assist From Chinese Data

36 PROBABILITY OF SUCCESS

37 LICENSING AND ASSET ACQUISITION DEALS

37 Deals Shaping The Medical Industry, April 2019

38 PARENT PATENTS

39 REVENUE OPPORTUNITY

40 CLINICAL TRIAL LANDSCAPE

41 Sponsors by status

42 Sponsors by phase

44 BIBLIOGRAPHY

45 Prescription information

46 APPENDIX

LIST OF FIGURES

  • 14 Figure 1: Global trends in incident cases of MCL, 2017-26
  • 16 Figure 2: Global incident cases of MCL, by age, 2017
  • 20 Figure 3: Overview of pipeline drugs for MCL in the US
  • 20 Figure 4: Pipeline drugs for MCL, by company
  • 21 Figure 5: Pipeline drugs for MCL, by drug type
  • 21 Figure 6: Pipeline drugs for MCL, by classification
  • 31 Figure 7: Brukinsa for MCL (December 1, 2018): Phase II - China
  • 33 Figure 8: Zanubrutinib for MCL (December 1, 2018): Phase I/II - B-Cell Malignancies (Australia)
  • 34 Figure 9: Key upcoming events in MCL
  • 36 Figure 10: Probability of success in the MCL pipeline
  • 37 Figure 11: Licensing and asset acquisition deals in MCL, 2014-19
  • 38 Figure 12: Parent patents in MCL
  • 40 Figure 13: Clinical trials in MCL
  • 40 Figure 14: Top 10 drugs for clinical trials in MCL
  • 41 Figure 15: Top 10 companies for clinical trials in MCL
  • 41 Figure 16: Trial locations in MCL
  • 42 Figure 17: MCL trials status
  • 43 Figure 18: MCL trials sponsors, by phase

LIST OF TABLES

  • 13 Table 1: Global incident cases of MCL, 2017-26
  • 15 Table 2: Global incident cases of MCL, by gender, 2017
  • 18 Table 3: Marketed drugs for MCL
  • 22 Table 4: Pipeline drugs for MCL in the US
  • 26 Table 5: Copiktra for MCL (July 25, 2019)
  • 27 Table 6: Copiktra for MCL (March 6, 2019)
  • 28 Table 7: Revlimid for MCL (February 27, 2019)
  • 29 Table 8: Zevalin for MCL (January 17, 2019)
  • 30 Table 9: Brukinsa for MCL (December 1, 2018)
  • 32 Table 10: Brukinsa for MCL (December 1, 2018)
  • 39 Table 11: Historical global sales, by drug ($m), 2014-18
  • 39 Table 12: Forecasted global sales, by drug ($m), 2019-23
Back to Top